Clinical Trial Update: AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial AK104 for MSI-H/dMMR gastric cancer and colorectal cancer has an active-not-recruiting status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Peking University | Conditions: MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING